{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypothyroidism/background-information/complications/","result":{"pageContext":{"chapter":{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field c0c2ad87-8aa4-451b-aeef-b1f5b4c923b3 --><h2>What are the complications?</h2><!-- end field c0c2ad87-8aa4-451b-aeef-b1f5b4c923b3 -->","summary":"","htmlStringContent":"<!-- begin item 7765ce62-42c2-4eb9-bb14-dd0575d08b54 --><!-- begin field abd4d180-f999-4426-b015-8d3178a04b56 --><div><strong>Complications of untreated or undertreated hypothyroidism include:</strong></div><ul><li><strong>Impaired quality of life</strong> due to symptoms such as fatigue.</li><li><strong>Cardiovascular</strong><ul><li>Dyslipidaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>]<ul><li>Several studies, including a large epidemiological survey (n = 25,862), have identified a relationship between increased thyroid-stimulating hormone (TSH) and dyslipidaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Canaris et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>].</li></ul></li><li>Metabolic syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>]<ul><li>Hypothyroidism is associated with a decrease in insulin sensitivity, including direct effects on insulin secretion and clearance, leading to potential insulin resistance and increased risk of developing metabolic syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>].</li></ul></li><li>Coronary heart disease (CHD) and stroke<ul><li>A large meta-analysis including over 50,000 people from 11 prospective cohort studies found a statistically significant association between CHD mortality at TSH levels greater than 7 mU/L, and for cardiovascular events at TSH levels greater than 10 mU/L [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Rodondi et al, 2010</a>].</li><li>Epidemiological studies have shown an association between subclinical hypothyroidism and CHD in people younger than 65 years of age, and in those with TSH levels higher than 10 mU/L [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Bekkering, 2019</a>]. The European Thyroid Association (ETA) guideline notes that the evidence regarding subclinical hypothyroidism and CHD events and mortality in the literature is conflicting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>].</li><li>A large meta-analysis of 55 cohort studies (n = 1,898,314) found that people with hypothyroidism, compared with euthyroid controls, had higher risks of ischaemic heart disease (relative risk [RR] 1.13), myocardial infarction (RR 1.15), cardiac mortality (RR 1.96), and all-cause mortality (RR 1.25). A diagnosis of SCH was also associated with an increased risk of ischaemic heart disease and all-cause mortality. It found no significant association between hypothyroidism and risk of stroke, heart failure, or atrial fibrillation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Ning, 2017</a>].</li><li>A retrospective cohort study of general practice patients with a diagnosis of hypothyroidism (n = 160,439) with a median follow-up of six years, found an increased risk of ischaemic heart disease and heart failure in people with high TSH concentrations (greater than 10 mU/L), with a hazard ratio of 1.18 and 1.42 respectively. In addition, increased all-cause mortality was observed with a hazard ratio of 2.21 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Thayakaran, 2019</a>].</li></ul></li><li>Heart failure<ul><li>Untreated overt hypothyroidism has been associated with an increased risk of diastolic heart failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Biondi, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>Subclinical hypothyroidism may be an independent risk factor for the development of heart failure and for progression of existing heart failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li></ul></li></ul></li><li><strong>Reproductive</strong><ul><li>Overt hypothyroidism is associated with:<ul><li>An increased risk of infertility and subfertility [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li></ul></li><li>Untreated overt hypothyroidism in pregnancy is associated with:<ul><li>An increased risk of miscarriage, anaemia, pre-eclampsia, placental abruption, postpartum haemorrhage, and stillbirth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>Adverse neonatal outcomes including preterm delivery, low birthweight, neonatal respiratory distress, congenital abnormalities, congenital hypothyroidism, and impaired fetal neurocognitive development [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li></ul></li><li>Untreated SCH and thyroid autoimmunity in pregnancy may be associated with:<ul><li>An increased risk of miscarriage, pregnancy loss, preterm delivery, low birthweight, gestational diabetes, gestational hypertension, and pre-eclampsia, but the evidence is conflicting in the literature [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Maraka, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Peeters, 2017</a>].</li></ul></li></ul></li><li><strong>Neurological and cognitive</strong><ul><li>Overt hypothyroidism is associated with:<ul><li>Decreased taste, vision, or hearing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>Impaired attention, concentration, memory, language, executive function, and psychomotor speed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Gaitonde et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li></ul></li><li>Data on the association between subclinical hypothyroidism and cognitive impairment are inconsistent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Biondi, 2019</a>].<ul><li>One systematic review and meta-analysis of 15 studies (n = 19,944) found no evidence of an association between subclinical hypothyroidism and cognitive impairment in adults over 60 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Akintola, 2015</a>].</li><li>A meta-analysis of 15 studies on the association between subclinical hypothyroidism and depression (n = 12,315) found that people with subclinical hypothyroidism had a higher risk of depression than euthyroid controls (relative risk 2.35), and this was particularly marked in the older population cohort [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Loh, 2019</a>].</li></ul></li></ul></li><li><strong>Myxoedema coma</strong><ul><li>This is a rare, life-threatening medical emergency due to untreated severe hypothyroidism, that may present with lethargy, bradycardia, hypothermia, seizures and/or coma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>Affected people are typically older and have previously undiagnosed hypothyroidism or are poorly compliant with thyroid hormone medication. The precipitant is usually onset of another condition such as heart failure, sepsis, or stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>].</li></ul></li></ul><!-- end field abd4d180-f999-4426-b015-8d3178a04b56 --><!-- end item 7765ce62-42c2-4eb9-bb14-dd0575d08b54 -->","topic":{"id":"f1d76bc1-c8dd-515b-a709-48c70c829658","topicId":"ebfc5032-6653-4b11-895c-5080f933e861","topicName":"Hypothyroidism","slug":"hypothyroidism","lastRevised":"Last revised in August 2020","chapters":[{"id":"cf0a606b-f582-5671-a84d-a1a3a12b7180","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"795eb9d9-4e15-51f6-81f4-7cc1b69ca74e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8d7a846-dfa6-5db5-ba95-fb161fd48c6e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d8567cc1-0642-5e9e-ad6c-8ca4abf5fa6e","slug":"changes","fullItemName":"Changes"},{"id":"c5e99cd1-e0c7-5efd-84bb-15bac6122b1d","slug":"update","fullItemName":"Update"}]},{"id":"2b8464ae-3182-517a-85be-6acc656616c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"17d5ebf3-bdca-50d2-a4f5-245d191f4973","slug":"goals","fullItemName":"Goals"},{"id":"9162c6a3-edc4-5319-9418-04b2cb656ce6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ae5c1d9-638e-52fa-b738-9561cd11b0ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fec82ae-e144-56a7-b1e8-8744c35e227e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"610f052f-83a2-5b06-b5e6-4aa272ef73a6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a578bde3-0d84-54f7-814d-18ed38e6038a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4b8f382f-673d-5804-8291-438e21e32790","slug":"definition","fullItemName":"Definition"},{"id":"ef0d96cd-207c-5814-93cf-c96870e2251d","slug":"causes","fullItemName":"Causes"},{"id":"09adb285-1d01-592a-9443-295b45c7d78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications"},{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cfe582c4-479a-5d44-b893-ac46a1a80b29","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6884c3db-6165-566b-a4ca-3e933de77714","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"42799fb8-7252-541e-9af1-27ebc28710b7","slug":"assessment","fullItemName":"Assessment"},{"id":"e850b740-b6cf-55a7-aed8-7372b7f13b05","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"d817ab4c-e7a3-582a-94fa-fcffd9c2d4f6","slug":"screening","fullItemName":"Screening"}]},{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","fullItemName":"Management","slug":"management","subChapters":[{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)"},{"id":"e358d249-a2f3-5a06-b301-2119af9ae164","slug":"subclinical-hypothyroidism-non-pregnant","fullItemName":"Scenario: Subclinical hypothyroidism (non-pregnant)"},{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant"},{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum"}]},{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine"}]},{"id":"2aaf1754-ba79-5b47-b2a5-74fe8f6af4da","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7669c894-3a85-55c7-b689-cb4b710a838a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"840d7de5-8c31-5696-9de6-c80ce1bbfec7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"299c20bf-2a22-5681-99ad-5f02f1395969","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd3df39b-4a5c-5416-af8d-dcdbf46bd255","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a88d4431-778a-5793-9557-9f806339a95b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1987302d-f600-55e0-a528-d3486c49048e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a49e5d2f-75e4-5219-a4d6-fd4a5595a776","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}